White Paper
Malaysia: The New Destination for Early Phase Trials
Malaysia’s emergence as a leading hub for early phase clinical trials, offering global sponsors access to accredited sites, diverse populations, and streamlined regulatory pathways.
Dec 02, 2025
Discover why Malaysia is rapidly becoming the preferred destination for early phase clinical trials in Asia Pacific. This white paper explores Malaysia’s unique value proposition—including its accredited trial sites, robust regulatory framework, and genetically diverse patient pool—enabling sponsors to conduct high-quality, globally relevant research. Learn how Malaysia’s infrastructure, government support, and operational efficiencies accelerate trial timelines and enhance data generalisability, supporting FDA and EMA submissions. Key topics include oncology, rare diseases, metabolic disorders, and the strategic advantages of conducting first-in-human studies in Malaysia.